ProteoCell develops bioprocess for the production of recombinant protein biotherapeutics in collaboration with other biotechnology companies. Every biomolecule advancement strategy has three critical components for advancing it towards the market: molecule discoverer, molecule producer, and clinical research organization to gain approval for commercialization. ProteoCell develops and produces the biomolecule in a scaleable format to allow for increasing quantities needed as it advances. ProteoCell uses mammalian and prokaryotic cell culture and purification technologies to produce candidate biotherapeutic molecules. ProteoCell has an advanced IP development program geared to building a unique production platform with the latest bioprocess technology for candidate client biomolecules. ProteoCell combines its in-house R&D capability with client biomolecule production needs to develop the suitable production platform at an early stage, eliminating costly, untimely, and cumbersome bioprocess change requirements later on. ProteoCell leverages its corporate partnerships to develop promising product candidates, expand its in-house technology, and accomplish tangible product advancement towards market. ProteoCell is open to different opportunities in private financing, including strategic partnerships and other capital sources. Investment proceeds are directed towards growth in the company's IP platform and cGMP capability development. For information on investment opportunities, please contact: Imad Nasrallah President Phone: (514) 299-3228 Email: inasrallah@proteocell.com
Lamda Biotech is a privately owned company. We invent, develop, sell, and support innovative technologies for life science researchers. For many years, Lamda Biotech has been known for novel, reliable, and efficient products in the field of molecular biology. Since the beginning of this new century, we have been expanding our technologies and products into the fields of functional genomics, proteomics, and gene therapy. Lamda Biotech's products are sold through a highly-trained direct sales force, an e-commerce website, and a network of distributors worldwide. We employ an extensive group of dynamic and talented research and development scientists to create unique and exciting products. We are committed to meeting and exceeding the highest scientific standards. The secret to our success is our 100% dedication to our customers; our creative, high-quality products; and our accurate, easily-accessible professional technical assistance.
http://www.creativebiolabs.com
Creative BioLabs [CD Inc] offers the most cost-effective custom protein expression services that cover gene synthesis, vector construction, expression optimization, fermentation and protein purification. Creative Biolabs has unparalleled capacity in delivering custom proteins in both small research and large preparative scale. Our GMP fermentation laboratories are equipped with 3.7-30 liter fermentors and Bioreactors that enable us to express protein in large scale. We produce recombinant proteins according to customer specifications or by developing customized protocols in house. Our customers can choose to enter into the protein expression pipeline at any stage depending on their needs.
Bio-Nobile Oy operates in marketing, application support, product development and manufacture, specializing in magnetic separation systems. The company supports applications in its two focal areas of nucleic acid purification and protein fractionation/purification with kits specifically optimized for use with the PickPen magnetic particle transfer system. Bio-Nobile has patented products and technologies for bioseparations specializing in magnetic separation systems, and maintains close contact and continuous collaboration with universities both in Finland and internationally.
Vector Biolabs is a biotechnology company focusing on the development of recombinant adenoviruses for the scientific community. Our goal is to help colleagues who are interested in using recombinant adenoviruses for their research, but don't have the time or internal resource to develop them. We are dedicated to provide the scientific community with high quality products, best services and technical supports. Please contact us if we can assist you in your research needs. We are located at the University City Science Center, inside the campus of University of Pennsylvania.
Nysa Membrane Technologies has developed a novel, patent-pending membrane-based platform technology with broad worldwide applications in protein purification and other biological & industrial separations. Nysa's proprietary membranes represent a truly disruptive technology, with dramatic cost and performance advantages over conventional membrane and resin-based separation technologies. Nysa has exploited its revolutionary technology to develop high value products for specific large and growing markets such as large-scale bioprocessing, small-scale bioanalytics, food & beverage processing, and water treatment.
Elchrom Scientific AG - the name reflects our focus on electrophoresis and chromatography - was founded in 1988 by scientists of the Swiss Federal Institute of Technology (ETH) in Zurich. In 1994, the company merged with Guest Medical to form Guest Elchrom Scientific group, from which Elchrom Scientific AG was separated in 1997. The company headquarters, R & D laboratories and manufacturing facilities are in Switzerland. At Elchrom Scientific AG we have directed our efforts towards the development of new materials and methodologies for the separation of biological macromolecules. Several of the developments have been successfully completed, and we are strongly committed to further R & D activities in this challenging area.
Cedarlane Laboratories Limited is an ISO 9001 and ISO 13485 certified privately held Canadian corporation. Cedarlane has been in business since 1957. It was incorporated in 1975 by three Canadian researchers originating from the University of Toronto and Ontario Cancer Institute; Dr. S. Abrahams, Dr. A.J. Farmilo and R.C. Course. The company has evolved to become a leading supplier of research reagents in Canada and world-wide, particularly in the area of immunology. It is located in Burlington, Ontario, Canada with close proximity to Pearson International Airport and the Toronto area. Cedarlane is both a manufacturer and distributor. Manufactured products include monoclonal antibodies, polyclonal antibodies, cell separation media, complement for tissue typing, and immunocolumns. These are available world-wide through a well-established network of international distributors. Products distributed within Canada are imported from over 500 international suppliers and are offered to our Canadian customer base of ~ 20,000 life science researchers. Cedarlane Shipping Supplies Inc. is a daughter company established ~ 5 years ago and specializes in providing shipping supplies for temperature-sensitive goods.
Islet Technology, Inc. (ITI) is a biomedical company focused on the processing and purification of insulin-producing islets to be supplied to transplant centers, eventually worldwide. Our core technologies are islet isolation and encapsulation. We are committed to seeing a cure for diabetes happen in our lifetimes. ITI has developed a valuable intellectual property portfolio covering both islet isolation and encapsulation, which we believe will provide the protection needed to effectively commercialize our islet processing services. Islet transplantation is currently in the final phase of human clinical trials begun in the year 2000. For the majority of participants in the trials, the need for externally administered insulin has either been eliminated or greatly reduced, making them insulin self-sufficient. In 2004, it is expected that data from these trials will be submitted to the FDA for approval in order to begin the process of making islet transplants more broadly available. In preparation for commercialization, ITI is in the process of establishing an islet processing center in the Minneapolis/St. Paul area of Minnesota. Once this facility is approved, ITI will be able to supply islets to transplant centers in the U.S. Much work needs to be done in many areas to ensure the availability of islet transplants. Fortunately on the reimbursement front, the recently-passed Medicare Prescription Drug Act established an important precedent by covering islet transplants within clinical trials involving Medicare patients with end stage renal disease. Private insurance companies look to Medicare for leadership in defining new treatments to be covered, so this Medicare study is an important milestone. Islet transplantation will grow as the source of islets expands. ITI expects that islet supply will progress from the current limited supply of deceased donors to include living donors (of partial pancreata), and eventually islets harvested from pigs - a virtually unlimited source. ITI's processing facilities will be able to handle the isolation of islets from all of these sources. When ITI's encapsulation technology is introduced in clinical trials, islets will also be encapsulated at ITI's processing center. Encapsulation involves coating islets with Algi-pure, our proprietary biocompatible material designed to protect islets from attack by the body's immune system. Encapsulation is expected to eliminate or greatly reduce the need for the transplant recipient to take immunosuppressive drugs.
Upstate develops innovative cell signaling products, technology platforms and services to accelerate your life science research and drug discovery efforts. Upstate has earned its reputation for developing the most thoroughly characterized and highest quality reagents, kits and services in our industry. Our commitment to the advancement of science has led to novel products and services that enable your passion for discovery. Our KinaseProfilerÔ selectivity screening service surpasses other similar services by over 40 available kinases, and our Beadlyte® Multiplex detection kits for the LuminexÔ detection technology are breaking new ground for multiplexing key cell signaling proteins, cytokines/chemokines and growth factors. In the past year, we have added over 500 new products and services to our offering, including new kinases, substrates and antibodies to post-translational modifications. In addition, we have greatly expanded our line of products for RNA Interference studies, introduced VisualizerÔ Western Blotting Kits for fast and sensitive protein detection, and added unique research reagents like Anti-Phosphatidylserine and Anti-Myc Tag, clone 4A6 , essential tools only available from Upstate. Your discoveries in cell signaling, and the advances in drug discovery they make possible, will revolutionize medicine in the years to come. Upstate is unwaveringly committed to supporting your work by providing products and services that help make your best efforts yield positive and useful results. Upstate is a Serologicals company. Serologicals Corporation is a global provider of consumable biological products, enabling technologies and services to a diverse customer base that includes major life science companies and leading research institutions. Our customers use our products, technologies and services in a wide variety of their activities, including basic research, drug discovery, diagnosis and biomanufacturing. Our products, technologies and services are essential tools for research in key disciplines, including neurology, oncology, hematology, immunology, cardiology, proteomics, infectious diseases, cell signaling, stem cell research and molecular biology.
http://www.tgr-biosciences.com.au
TGR BioSciences Pty Ltd (TGR) is a private biotechnology company based in Adelaide, South Australia. TGR's primary business focus is on the discovery and development of scientifically proven products that can be marketed as high-value therapies in oral and gastro-intestinal health, skin and tissue repair. A lead product is in clinical trials for the prevention of oral mucositis, the debilitating mouth ulcers that affect over 40% of all chemotherapy patients and 60% of head-neck radiotherapy patients. TGR has a number of products in development targeted towards wound repair, tissue engineering, skin regeneration, and dermatology.
Novasep serves Life Sciences industries, such as human health, animal health, cosmetics, food additives, agrochemicals. Novasep designs purification processes aimed at producing a variety of biomolecules like: Vaccines and vitamins Proteins and enzymes Peptides and antibiotics Milk proteins and amino acid derivatives Sweeteners of various types The synthesis of organic molecules, either advanced intermediates or APIs (Active Pharlaceutical Ingredients) is often carried out by integrating the purification technologies mastered by the group. This combination that impoves synthetic pathways of molecules is used every day to develop and produce our customers' innovative drugs. Current applications are found with drugs that treat: Cancer Cardiovascular disorders, i.e. high blood pressure
QSV Biologics, Ltd. is a North American based cGMP biologics contract manufacturer providing mammalian cell culture, microbial fermentation and purification services for the production of protein therapeutics, monoclonal antibodies, vaccines and diagnostics. Our facility has a 10 year track record and is licensed for cGMP manufacture of pre-clinical, clinical and commercial supply. QSV recently underwent a comprehensive GMP compliance audit by Health Canada's Health Products and Food Branch Inspectorate (HPFBI) and was found to be compliant with all applicable regulations and guidelines. QSV's market consists of Canadian, U.S., Australian, Asian and European biotechnology firms with protein therapeutics in development. As a dedicated biopharmaceutical contract manufacturer, QSV provides the following services: cGMP Microbial Fermentation Microbial Process Development Upstream and Downstream Mammalian Cell Culture Process Development Upstream and Downstream cGMP Cell Bank Development & Storage Analytical Development Process & Analytical Validation Process Scale Up cGMP Document Services Technology Transfer Quality is your first consideration when selecting a contract manufacturer. Quality is our first priority! More information can be obtained by contacting: Richard Hetrick Business Development Phone: (484) 678 - 4820 Phone: (780) 438 - 7143 Fax: (610) 873 - 8453 Email: rhetrick@qsvbiologics.com
EPICENTRE®, founded in 1987, is a manufacturer and seller of high-quality molecular biology products for life science research, clinical research, molecular diagnostics and biopharmaceutical manufacturing. Products are available for transposon-based genetic analysis, DNA and RNA purification, DNA sequencing, PCR and RT-PCR amplification, DNA and RNA modifying enzymes, genomic cloning, in vitro transcription, and protein research.
Lipidviro Tech, Inc. is a development-stage biotechnology company engaged in research and commercial development of two primary platforms: d-OSAB Therapy, a treatment targeting cardiovascular disease and stroke, and PathPure, a purification process for production of pathogen-free biologics. LipidViro d-OSAB Therapy is a re-engineered doseable form of a traditional therapy known as OSAB-uc for uncontrolled dosing. On January 3, 2008, the Company entered into an Agreement with AcquiSci, Inc., (AcquiSci), and its wholly owned subsidiary, LipidViro Tech, Inc., (LipidViro Utah), by which LipidViro granted to AcquiSci an option to purchase the technology that constitutes substantially all of its assets (the Technology). (Source: 10KSB)
Ellipsis Biotherapeutics Corporation is a privately held drug and diagnostic discovery company developing novel medicines for human diseases where existing therapies are unable to address patient needs. The company's lead programs are in Alzheimer's Disease and Inflammatory Bowel Disease, where new treatment regimens are needed not only to treat symptoms, but to prevent and cure the underlying disorder. Through both independent programs and strategic alliances, Ellipsis intends to commercialize its discoveries and make better medicines for patients.
Norgen Biotek offers plasmid amplification and purification services that can be customized to your needs. Norgen's team of skilled scientists uses their proprietary, resin-based system in order to obtain a plasmid preparation of the highest quality. We offer both competitive pricing and fast turnaround times. We are confident that Norgen's plasmid purification service will be able to meet your research needs. Norgen currently offers the following grade of DNA: Standard Research Grade This plasmid DNA can be used for standard research purposes such as cloning, sequencing, transformations, and transfections. These preparations are guaranteed to be free of genomic DNA, RNA and protein.
Omrix Biopharmaceuticals, Inc. is a fully integrated biopharmaceutical company that develops, manufactures and markets protein-based biosurgery and passive immunotherapy products derived from human plasma by utilizing protein purification technology and manufacturing know-how. The biosurgery product line includes products and product candidates that are used for the control of bleeding, or hemostasis, and other surgical applications. The passive immunotherapy product line includes antibody-rich products and products for the treatment of immune deficiencies, infectious diseases and potential biodefense applications, such as VIG, which is designed to treat complications related to the smallpox vaccination. The Company's Israeli subsidiary, Omrix Ltd., performs most of research and development, as well as manufacturing activities. European activities are managed primarily from the Company's Belgian subsidiary, Omrix Biopharmaceuticals S.A. (Source: 10-K)
Hemosol BioPharma Inc. (Hemosol) is an integrated biopharmaceutical company that develops and manufactures therapeutic biological products, particularly blood-related protein based therapeutics. The company is pursuing a strategy to manufacture and market therapeutic products for the North American market. Hemosol possesses a strong understanding of the market and business opportunities for therapeutic proteins and experience in the development and manufacture of biological products. Hemosol's extensive pipeline of products address unmet medical needs in major medical markets. Such products include protein-based therapeutics to treat infectious disease, cancer and anemia. The Company's activities are focused in the following three areas: Implementation of the "Cascade" technology for the isolation and purification of plasma proteins. This disruptive technology has the potential to change the business dynamics of the therapeutic plasma proteins sector.
ProMetic Life Sciences Inc. is a global biopharmaceutical company offering technologies for large-scale drug purification, drug development, proteomics, clinical diagnostics, and the elimination of pathogens. The Company is developing products to treat anemia, neutropenia, cancer and autoimmune disease/inflammation. ProMetic uses its Affinity Technology, which employs its Mimetic Ligand technology to facilitate a variety of applications where a target biomolecule requires purification or removal. The Company operates in three units, each of which is a subsidiary controlled by the Company: ProMetic BioSciences Ltd, ProMetic BioTherapeutics, Inc. and ProMetic BioSciences Inc. The Company focuses its activities in two distinct fields: therapeutics and protein technologies. ProMetic develops therapeutics to treat blood-related disorders. ProMetic’s protein technologies are used to remove pathogens from blood and extract and recover valuable proteins from plasma. (Source: ARS)
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory